![Special Analysis: Addressing Key Concerns Around the FDA’s Final LDTs Rule](https://www.g2intelligence.com/wp-content/uploads/2024/07/July24.LIA_.SpecialAnalysis.LDTsQuestionsandAnswers.SW-iStock-1478718567-1100x800-1-1080x675.jpg)
Special Analysis: Addressing Key Concerns Around the FDA’s Final LDTs Rule
Experts answer key questions related to laboratory-developed test regulation during G2 Intelligence webinar.
Experts answer key questions related to laboratory-developed test regulation during G2 Intelligence webinar.
The grants, which include $3 million from the NIH and $1 million from the NSF, will help the company develop point-of-care tests
Clinical laboratory professionals must consider how race affects test referrals and what they can do to combat existing inequities
Approval for OTC use of a urine drug test that can be performed by non-CLIA facilities could help expand accessibility, expert says.
Rachel Rangel, AuD, discusses a new toolkit to help laboratory professionals ensure diversity and inclusion is addressed in their research.